Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
In a report issued today, analysts said the company failed to provide "meaningfully improved visibility on broader reimbursement and revenue progression."
The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.
In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.
The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.
Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.